Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium difficile Vaccine in the United States

An article from Biospace
August 5, 2013
Sanofi Pasteur Initiates Phase III Study of Investigational Clostridium difficile Vaccine in the United States

 

August 5, 2013 -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.

Read the rest of the press release here.